187 related articles for article (PubMed ID: 23473850)
1. Podoplanin expression in oral leukoplakia: tumorigenic role.
de Vicente JC; Rodrigo JP; Rodriguez-Santamarta T; Lequerica-Fernández P; Allonca E; García-Pedrero JM
Oral Oncol; 2013 Jun; 49(6):598-603. PubMed ID: 23473850
[TBL] [Abstract][Full Text] [Related]
2. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.
Kawaguchi H; El-Naggar AK; Papadimitrakopoulou V; Ren H; Fan YH; Feng L; Lee JJ; Kim E; Hong WK; Lippman SM; Mao L
J Clin Oncol; 2008 Jan; 26(3):354-60. PubMed ID: 18202409
[TBL] [Abstract][Full Text] [Related]
3. Podoplanin expression in oral leukoplakia: prognostic value and clinicopathological implications.
Kreppel M; Kreppel B; Drebber U; Wedemayer I; Rothamel D; Zöller JE; Scheer M
Oral Dis; 2012 Oct; 18(7):692-9. PubMed ID: 22471854
[TBL] [Abstract][Full Text] [Related]
4. [Podoplanin expression in oral squamous cell carcinoma and leukoplakia and its correlation with lymph vessels density].
Zhang G; Guo ZL; Gao Y
Zhonghua Kou Qiang Yi Xue Za Zhi; 2009 Aug; 44(8):488-91. PubMed ID: 19961757
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical Expression of Podoplanin in Clinical Variants of Oral Leukoplakia and Its Correlation With Epithelial Dysplasia.
D'souza B; Nayak R; Kotrashetti VS
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):132-139. PubMed ID: 27153448
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of cornulin, keratin 4, keratin 13 expression and grade of dysplasia for predicting malignant progression of oral leukoplakia.
Schaaij-Visser TB; Bremmer JF; Braakhuis BJ; Heck AJ; Slijper M; van der Waal I; Brakenhoff RH
Oral Oncol; 2010 Feb; 46(2):123-7. PubMed ID: 20036603
[TBL] [Abstract][Full Text] [Related]
7. Podoplanin expression as a predictive marker of dysplasia in oral leukoplakia.
Gissi DB; Gabusi A; Tarsitano A; Luccarini L; Morandi L; Montebugnoli L
J Craniomaxillofac Surg; 2018 May; 46(5):759-764. PubMed ID: 29588189
[TBL] [Abstract][Full Text] [Related]
8. E-cadherin as a potential biomarker of malignant transformation in oral leukoplakia: a retrospective cohort study.
von Zeidler SV; de Souza Botelho T; Mendonça EF; Batista AC
BMC Cancer; 2014 Dec; 14():972. PubMed ID: 25518919
[TBL] [Abstract][Full Text] [Related]
9. Alterations of rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinoma.
Soni S; Kaur J; Kumar A; Chakravarti N; Mathur M; Bahadur S; Shukla NK; Deo SV; Ralhan R
Oncology; 2005; 68(4-6):314-25. PubMed ID: 16020958
[TBL] [Abstract][Full Text] [Related]
10. Podoplanin expression in oral leukoplakia─a prospective study.
Grochau KJ; Safi AF; Drebber U; Grandoch A; Zöller JE; Kreppel M
J Craniomaxillofac Surg; 2019 Mar; 47(3):505-509. PubMed ID: 30638740
[TBL] [Abstract][Full Text] [Related]
11. Expression of podoplanin in oral premalignant and malignant lesions and its potential as a biomarker.
Logeswari J; Malathi N; Thamizhchelvan H; Sangeetha N; Nirmala SV
Indian J Dent Res; 2014; 25(3):305-10. PubMed ID: 25098985
[TBL] [Abstract][Full Text] [Related]
12. p53 immunoprofiling of potentially malignant oral disorders: a case series analysis.
Reddy VM; Kamath A; Radhakrishnan RA
Indian J Cancer; 2012; 49(1):27-32. PubMed ID: 22842165
[TBL] [Abstract][Full Text] [Related]
13. Podoplanin and VEGF-C immunoexpression in oral squamous cell carcinomas: prognostic significance.
dos Santos Almeida A; Oliveira DT; Pereira MC; Faustino SE; Nonogaki S; Carvalho AL; Kowalski LP
Anticancer Res; 2013 Sep; 33(9):3969-76. PubMed ID: 24023336
[TBL] [Abstract][Full Text] [Related]
14. p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma.
Cruz IB; Snijders PJ; Meijer CJ; Braakhuis BJ; Snow GB; Walboomers JM; van der Waal I
J Pathol; 1998 Apr; 184(4):360-8. PubMed ID: 9664901
[TBL] [Abstract][Full Text] [Related]
15. Enhanced expression of podoplanin in oral carcinomas in situ and squamous cell carcinomas.
Funayama A; Cheng J; Maruyama S; Yamazaki M; Kobayashi T; Syafriadi M; Kundu S; Shingaki S; Saito C; Saku T
Pathobiology; 2011; 78(3):171-80. PubMed ID: 21613804
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of MAGE-A expression and grade of dysplasia for predicting malignant progression of oral leukoplakia.
Ries J; Agaimy A; Vairaktaris E; Kwon Y; Neukam FW; Strassburg LH; Nkenke E
Int J Oncol; 2012 Sep; 41(3):1085-93. PubMed ID: 22751922
[TBL] [Abstract][Full Text] [Related]
17. Podoplanin Expression Independently and Jointly with Oral Epithelial Dysplasia Grade Acts as a Potential Biomarker of Malignant Transformation in Oral Leukoplakia.
Monteiro L; do Amaral B; Delgado L; Garcês F; Salazar F; Pacheco JJ; Lopes C; Warnakulasuriya S
Biomolecules; 2022 Apr; 12(5):. PubMed ID: 35625534
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome.
Yuan P; Temam S; El-Naggar A; Zhou X; Liu DD; Lee JJ; Mao L
Cancer; 2006 Aug; 107(3):563-9. PubMed ID: 16804930
[TBL] [Abstract][Full Text] [Related]
19. The relevance of EGFR overexpression for the prediction of the malignant transformation of oral leukoplakia.
Ries J; Vairaktaris E; Agaimy A; Bechtold M; Gorecki P; Neukam FW; Nkenke E
Oncol Rep; 2013 Sep; 30(3):1149-56. PubMed ID: 23784518
[TBL] [Abstract][Full Text] [Related]
20. [Molecular risk markers for malignant transformation of oral mucosal leukoplakia ].
Skorodumova LO; Muriaev AA; Volodina EV; Ivanov SIu; Gnuchev NV; Georgiev GP; Larin SS
Vopr Onkol; 2012; 58(3):327-32. PubMed ID: 22888646
[No Abstract] [Full Text] [Related]
[Next] [New Search]
